Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:37:17.064Z.
Calculation as of: 2026-10-06T13:37:17.064Z.
Quote observation: 2026-10-06T13:31:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cc1b6a3b00dabe5b261e15a58cf0fecaa0dcd4715ed4b38f5f86d2c12a5f1f47
PE RATIO
N/A
Market Cap
$1.03M
PE Ratio
N/A
TTM Avg
173046.93
3Y Avg
281427.36
5Y Avg
281427.36
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cellyan Biotechnology Co., Ltd (HKPD) | $1.14M | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.15M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.09M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.03M | N/A | 173046.93 | 281427.36 | 281427.36 |
| GlucoTrack, Inc. (GCTK)vs › | $893920.00 | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | N/A | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $867353.00 | N/A | 0.00 | 0.00 | 0.00 |
| Genprex, Inc. (GNPX)vs › | $1.35M | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $883067.00 | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
